NEXT Financial Group Inc Has $2.18 Million Stock Position in Chemours Co (NYSE:CC)

NEXT Financial Group Inc lifted its holdings in shares of Chemours Co (NYSE:CC) by 21,994.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 90,809 shares of the specialty chemicals company’s stock after acquiring an additional 90,398 shares during the period. NEXT Financial Group Inc’s holdings in Chemours were worth $2,179,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Cullen Frost Bankers Inc. acquired a new stake in shares of Chemours in the first quarter valued at about $26,000. Investors Research Corp increased its stake in shares of Chemours by 148.1% in the second quarter. Investors Research Corp now owns 1,206 shares of the specialty chemicals company’s stock valued at $29,000 after buying an additional 720 shares during the period. Zions Bancorporation N.A. acquired a new stake in shares of Chemours in the first quarter valued at about $30,000. Enterprise Financial Services Corp increased its stake in shares of Chemours by 306.5% in the first quarter. Enterprise Financial Services Corp now owns 935 shares of the specialty chemicals company’s stock valued at $34,000 after buying an additional 705 shares during the period. Finally, Legacy Bridge LLC increased its stake in shares of Chemours by 100.0% in the first quarter. Legacy Bridge LLC now owns 1,200 shares of the specialty chemicals company’s stock valued at $45,000 after buying an additional 600 shares during the period. 80.36% of the stock is owned by institutional investors and hedge funds.

CC stock opened at $19.32 on Wednesday. Chemours Co has a twelve month low of $18.14 and a twelve month high of $48.97. The company has a quick ratio of 1.04, a current ratio of 1.81 and a debt-to-equity ratio of 5.18. The firm has a 50 day moving average of $21.66. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 3.41, a PEG ratio of 0.32 and a beta of 2.51.

Chemours (NYSE:CC) last posted its earnings results on Thursday, May 2nd. The specialty chemicals company reported $0.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.93 by ($0.30). Chemours had a net margin of 12.60% and a return on equity of 87.75%. The company had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the prior year, the business earned $1.41 EPS. The firm’s revenue for the quarter was down 20.5% compared to the same quarter last year. On average, research analysts expect that Chemours Co will post 3.92 EPS for the current year.

Several equities research analysts have recently weighed in on CC shares. Jefferies Financial Group decreased their price target on Chemours from $48.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, June 10th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Morgan Stanley reiterated an “overweight” rating on shares of in a report on Wednesday, June 19th. Royal Bank of Canada cut their price target on Toromont Industries from C$66.00 to C$65.00 and set a “sector perform” rating on the stock in a report on Monday, May 6th. Finally, Citigroup upgraded Infosys from a “neutral” rating to a “buy” rating in a report on Friday, July 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. Chemours currently has an average rating of “Hold” and an average price target of $38.10.

In other Chemours news, Director Bradley J. Bell purchased 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was bought at an average cost of $24.06 per share, with a total value of $120,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark P. Vergnano purchased 44,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $23.17 per share, with a total value of $1,019,480.00. Following the completion of the transaction, the chief executive officer now directly owns 116,600 shares of the company’s stock, valued at approximately $2,701,622. The disclosure for this purchase can be found here. Insiders bought 55,500 shares of company stock worth $1,289,670 in the last 90 days. Corporate insiders own 2.34% of the company’s stock.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: Overbought

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.